ArticleScientific reports2026
Interpretability of multimodal neural networks for prediction of visual acuity in patients with branch retinal vein occlusion.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Branch retinal vein occlusion (BRVO) can cause persistent visual impairment, and predicting long-term best-corrected visual acuity (BCVA) after anti-vascular endothelial growth factor treatment remains clinically challenging. This retrospective proof-of-concept study developed multimodal neural networks to predict 12-month BCVA classes using retinal images and clinical metadata from treatment-naive BRVO eyes. The best internal model used OCT-horizontal scans, OCTA images, baseline BCVA, central subfield thickness, age, and sex. We evaluated performance using adjacent accuracy, exact accuracy, and mean absolute error under five-fold cross-validation, and we analyzed attribution localization using Pathway Attribution. We additionally performed a supplementary exploratory cross-disease feasibility analysis using an available diabetic macular edema (DME) OCT cohort with 24-month visual acuity outcomes. This analysis was interpreted only as supplementary exploratory feasibility evidence and not as disease-matched BRVO external validation. Overall, the results suggest that multimodal imaging and clinical metadata may provide complementary prognostic information after BRVO, but the modest predictive performance, retrospective single-center design, lack of disease-matched external validation, and limited attribution reliability require cautious interpretation and further prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.